This article is more than 5 years old. Information may no longer be current.

STAAR Surgical receives approval of EVO Visian toric ICL from Health Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

STAAR Surgical announced the Medical Devices Bureau of Health Canada approved the EVO Visian toric ICL for distribution in Canada.

In contrast to traditional contact lenses that are placed on the surface of the eye, the EVO toric ICL is placed inside the eye between the iris and natural lens, where it stays indefinitely, according to a company press release.

Clinical data show that the EVO ICL provides predictable correction of high degrees of refractive errors, with the majority of patients achieving and maintaining 20/20 or better visual acuity through a 5-year follow up.

“We are very pleased with Health Canada’s approval that allows us to offer the EVO toric ICL for myopia and astigmatism, with a broad spherical power range of –3 D to –18 D and cylinder power range of 1 D to 6 D, to our surgeons and their patients in Canada,” Caren Mason, president and CEO of STAAR, said in the release.